Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (41-50 of 477) with videos related to

Pageof 48
Sort By:
The Journal of Rheumatology|May 5, 2007
Rationale and strategies for reevaluating the ACR20David T Felson, Daniel E Furst, Maarten Boers
Current Rheumatology Reports|May 16, 2007
Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FASTNihal Fathi, Daniel E Furst, Philip J Clements
Rheumatology (Oxford, England)|October 10, 2017
Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosisDaniel E Furst, Yolanda Braun-Moscovic, Dinesh Khanna
Journal of Scleroderma and Related Disorders|April 6, 2022
Hematopoietic stem cell transplantation in systemic sclerosis: Yes!! BUT. . Khitam A AlOdhaibi, John Varga, Daniel E Furst
Arthritis and Rheumatism|October 3, 2006
Cyclooxygenase 2 controversy: thoughts on the process of discovery, development, and assessment of benefit and risk of therapies for chronic immunoinflammatory diseases of uncertain autoimmune etiologyDaniel E Furst, Dinesh Khanna, Harold E Paulus
Autoimmunity Reviews|September 3, 2005
Hemopoietic stem cell transplantation in rheumatic diseases--an updatePaige de Buys, Dinesh Khanna, Daniel E Furst
Biologics : Targets & Therapy|March 4, 2017
Biosimilars and the extrapolation of indications for inflammatory conditionsJohn Rp Tesser, Daniel E Furst, Ira Jacobs
Clinical Immunology (Orlando, Fla.)|February 10, 2019
Genetic and inflammatory factors associated with psoriatic arthritis: Relevance to diagnosis and managementDaniel E Furst, Jennifer Belasco, James S Louie
Inflammopharmacology|December 16, 2005
COX-2 controversy: where are we and where do we go from here?Dinesh Khanna, Puja P Khanna, Daniel E Furst
Rheumatology (Oxford, England)|October 10, 2017
Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosisDinesh Khanna, Ron D Hays, Daniel E Furst
Pageof 48

Showing results (41-50 of 477) with videos related to

Sort By:
Pageof 48
The Journal of Rheumatology|May 5, 2007
Rationale and strategies for reevaluating the ACR20David T Felson, Daniel E Furst, Maarten Boers
Current Rheumatology Reports|May 16, 2007
Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FASTNihal Fathi, Daniel E Furst, Philip J Clements
Rheumatology (Oxford, England)|October 10, 2017
Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosisDaniel E Furst, Yolanda Braun-Moscovic, Dinesh Khanna
Journal of Scleroderma and Related Disorders|April 6, 2022
Hematopoietic stem cell transplantation in systemic sclerosis: Yes!! BUT. . Khitam A AlOdhaibi, John Varga, Daniel E Furst
Arthritis and Rheumatism|October 3, 2006
Cyclooxygenase 2 controversy: thoughts on the process of discovery, development, and assessment of benefit and risk of therapies for chronic immunoinflammatory diseases of uncertain autoimmune etiologyDaniel E Furst, Dinesh Khanna, Harold E Paulus
Autoimmunity Reviews|September 3, 2005
Hemopoietic stem cell transplantation in rheumatic diseases--an updatePaige de Buys, Dinesh Khanna, Daniel E Furst
Biologics : Targets & Therapy|March 4, 2017
Biosimilars and the extrapolation of indications for inflammatory conditionsJohn Rp Tesser, Daniel E Furst, Ira Jacobs
Clinical Immunology (Orlando, Fla.)|February 10, 2019
Genetic and inflammatory factors associated with psoriatic arthritis: Relevance to diagnosis and managementDaniel E Furst, Jennifer Belasco, James S Louie
Inflammopharmacology|December 16, 2005
COX-2 controversy: where are we and where do we go from here?Dinesh Khanna, Puja P Khanna, Daniel E Furst
Rheumatology (Oxford, England)|October 10, 2017
Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosisDinesh Khanna, Ron D Hays, Daniel E Furst
Pageof 48